Literature DB >> 3257913

Pharmacokinetics of leucovorin calcium after intravenous, intramuscular, and oral administration.

B W McGuire1, L L Sia, P T Leese, M L Gutierrez, E L Stokstad.   

Abstract

The pharmacokinetics of leucovorin was evaluated after intravenous, intramuscular, and oral administration in a randomized crossover study of 37 healthy men. A single 25-mg dose of leucovorin calcium was administered intravenously, intramuscularly, or orally to the subjects. Blood samples were obtained immediately before and at 13 time points up to 24 hours after the leucovorin dose. The three treatment phases were separated by one-week intervals. Bioavailability was assessed by measuring over 24 hours the blood concentrations of total folates, the parent compound 5-formyltetrahydrofolate, and the metabolite 5-methyltetrahydrofolate, using differential microbiologic assays with Lactobacillus casei and Streptococcus faecalis. Both intravenous and intramuscular administration produced rapid increases in serum concentrations of biologically active folates; these rises were sustained over time and were still detectable at 24 hours after drug administration. The bioavailability of intravenous and intramuscular doses was comparable based on area under the serum concentration-time curve, although for intramuscular administration, the peak concentration was lower and the time to peak concentration was longer. The initial rise in serum folate with intravenous and intramuscular dosing represented 5-formyltetrahydrofolate; this fell concomitantly with the appearance of 5-methyltetrahydrofolate. Oral leucovorin was 92% bioavailable compared with intravenous administration and produced a predictably different pattern of circulating folates, 5-methyltetrahydrofolate being the predominant form. Terminal elimination half-life, apparent volume of distribution, and clearance of total folate were not significantly different among the three treatments.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3257913

Source DB:  PubMed          Journal:  Clin Pharm        ISSN: 0278-2677


  4 in total

1.  Bioactivity of [6R]-5-formyltetrahydrofolate, an unusual isomer, in humans and Enterococcus hirae, and cytochrome c oxidation of 10-formytetrahydrofolate to 10-formyldihydrofolate.

Authors:  J E Baggott; C B Robinson; K E Johnston
Journal:  Biochem J       Date:  2001-02-15       Impact factor: 3.857

2.  Pharmacokinetic comparison of leucovorin and levoleucovorin.

Authors:  J Zittoun; A P Tonelli; J Marquet; E De Gialluly; C Hancock; A Yacobi; J B Johnson
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

3.  Stereospecific pharmacokinetics of rac-5-methyltetrahydrofolic acid in patients with advanced colorectal cancer.

Authors:  R M Mader; G G Steger; B Rizovski; M P Djavanmard; W Scheithauer; R Jakesz; H Rainer
Journal:  Br J Clin Pharmacol       Date:  1995-09       Impact factor: 4.335

4.  A pharmacokinetic comparison of intravenous versus intra-arterial folinic acid.

Authors:  J H Anderson; D J Kerr; A Setanoians; T G Cooke; C S McArdle
Journal:  Br J Cancer       Date:  1992-01       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.